Extracellular Vesicle-Mediated Metastasis Suppressors NME1 and NME2 Modify Lipid Metabolism in Fibroblasts.
NME
exosomes
extracellular vesicles
fatty acid metabolism
lipid metabolism
metastasis suppressor
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
13 Aug 2022
13 Aug 2022
Historique:
received:
21
06
2022
revised:
07
08
2022
accepted:
09
08
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
27
8
2022
Statut:
epublish
Résumé
Nowadays, extracellular vesicles (EVs) raise a great interest as they are implicated in intercellular communication between cancer and stromal cells. Our aim was to understand how vesicular NME1 and NME2 released by breast cancer cells influence the tumour microenvironment. As a model, we used human invasive breast carcinoma cells overexpressing NME1 or NME2, and first analysed in detail the presence of both isoforms in EV subtypes by capillary Western immunoassay (WES) and immunoelectron microscopy. Data obtained by both methods showed that NME1 was present in medium-sized EVs or microvesicles, whereas NME2 was abundant in both microvesicles and small-sized EVs or exosomes. Next, human skin-derived fibroblasts were treated with NME1 or NME2 containing EVs, and subsequently mRNA expression changes in fibroblasts were examined. RNAseq results showed that the expression of fatty acid and cholesterol metabolism-related genes was decreased significantly in response to NME1 or NME2 containing EV treatment. We found that
Identifiants
pubmed: 36010906
pii: cancers14163913
doi: 10.3390/cancers14163913
pmc: PMC9406105
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : National Research, Development and Innovation Fund of Hungary
ID : FIEK 16
Organisme : Hungarian Ministry of Human Capacities
ID : ELTE Institutional Excellence Program (1783-3/2018/FEKUTSRAT)
Références
Molecules. 2020 Aug 28;25(17):
pubmed: 32872164
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Mol Cell Endocrinol. 2018 Feb 15;462(Pt B):93-106
pubmed: 28119133
Blood. 2001 Mar 1;97(5):1202-10
pubmed: 11222361
J Natl Cancer Inst. 1994 Dec 21;86(24):1838-44
pubmed: 7990158
Biochem Biophys Res Commun. 1992 Feb 14;182(3):987-94
pubmed: 1311576
Br J Cancer. 2007 Nov 19;97(10):1372-80
pubmed: 17940513
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Naunyn Schmiedebergs Arch Pharmacol. 2011 Oct;384(4-5):397-406
pubmed: 21556888
Biomed Environ Sci. 2010 Aug;23(4):267-72
pubmed: 20934113
Adv Drug Deliv Rev. 2020;159:245-293
pubmed: 32711004
J Bioenerg Biomembr. 2003 Feb;35(1):73-9
pubmed: 12848344
Genome Biol. 2009;10(3):R25
pubmed: 19261174
Cancers (Basel). 2021 Sep 21;13(18):
pubmed: 34572947
Proc Natl Acad Sci U S A. 2018 Oct 2;115(40):E9499-E9506
pubmed: 30228117
Nucleic Acids Res. 2012 May;40(10):4288-97
pubmed: 22287627
Clin Exp Metastasis. 2003;20(1):3-10
pubmed: 12650601
Cell Mol Immunol. 2022 Mar;19(3):432-444
pubmed: 34983949
Blood. 2000 Aug 1;96(3):1080-6
pubmed: 10910925
Clin Cancer Res. 2006 Jul 1;12(13):3882-9
pubmed: 16818682
Signal Transduct Target Ther. 2020 Aug 5;5(1):145
pubmed: 32759948
J Bioenerg Biomembr. 2006 Aug;38(3-4):169-75
pubmed: 16944304
J Natl Cancer Inst. 1988 Apr 6;80(3):200-4
pubmed: 3346912
Lab Invest. 2018 Mar;98(3):304-314
pubmed: 29400699
Cancers (Basel). 2020 Sep 03;12(9):
pubmed: 32899149
Cancer Sci. 2005 Oct;96(10):653-60
pubmed: 16232196
J Exp Med. 2020 Aug 3;217(8):
pubmed: 32491160
Cancers (Basel). 2021 Jun 22;13(13):
pubmed: 34206705
Integr Cancer Sci Ther. 2015;2(4):192-200
pubmed: 26413311
J Bioenerg Biomembr. 2000 Jun;32(3):301-8
pubmed: 11768314
Proc Natl Acad Sci U S A. 2022 Mar 15;119(11):e2117013119
pubmed: 35259022
Nanoscale. 2022 Feb 24;14(8):2998-3003
pubmed: 35141731
Clin Cancer Res. 2012 Apr 1;18(7):2012-23
pubmed: 22328561
Leukemia. 2003 Jan;17(1):196-202
pubmed: 12529678
J Natl Cancer Inst. 2005 Jun 1;97(11):836-45
pubmed: 15928304
Br J Cancer. 2009 May 5;100(9):1465-70
pubmed: 19367276
Cancer Res. 1992 Nov 1;52(21):6088-91
pubmed: 1356624
Front Oncol. 2022 Apr 28;12:898605
pubmed: 35574366
Pharmacol Rev. 2012 Jul;64(3):676-705
pubmed: 22722893
Mol Cell Biochem. 2009 Sep;329(1-2):51-62
pubmed: 19387795
Naunyn Schmiedebergs Arch Pharmacol. 2011 Oct;384(4-5):489-98
pubmed: 21553004
Br J Cancer. 1994 Dec;70(6):1224-8
pubmed: 7981081
Lab Invest. 2018 May;98(5):602-608
pubmed: 29339833
J Biol Chem. 1998 Aug 7;273(32):20121-7
pubmed: 9685355
Nature. 1994 Aug 4;370(6488):335-6
pubmed: 8047138
Lab Invest. 2018 Mar;98(3):327-338
pubmed: 29058705
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Genome Biol. 2013 Apr 25;14(4):R36
pubmed: 23618408
Curr Opin Cell Biol. 2009 Aug;21(4):575-81
pubmed: 19442504
Cancer Discov. 2022 Jan;12(1):31-46
pubmed: 35022204
BMC Evol Biol. 2009 Oct 23;9:256
pubmed: 19852809
Science. 2011 Mar 25;331(6024):1559-64
pubmed: 21436443
Int J Cancer. 1996 Oct 21;69(5):415-9
pubmed: 8900377
Int J Surg. 2018 Dec;60:257-265
pubmed: 30389538
Cancer Metastasis Rev. 2021 Dec;40(4):989-1033
pubmed: 35029792
Proc West Pharmacol Soc. 2001;44:61-3
pubmed: 11793996
Sci Rep. 2016 Nov 24;6:37643
pubmed: 27883084
Gen Pharmacol. 1985;16(5):433-40
pubmed: 2996968
Cancer Res. 1989 Sep 15;49(18):5185-90
pubmed: 2475243
Clin Exp Metastasis. 2011 Dec;28(8):733-41
pubmed: 21744083
Cell Death Dis. 2020 Apr 23;11(4):267
pubmed: 32327627
J Proteomics. 2011 May 16;74(6):874-86
pubmed: 21385632
Lab Invest. 2018 Feb;98(2):248-257
pubmed: 29035383
Nucleic Acids Res. 2009 Jul;37(Web Server issue):W305-11
pubmed: 19465376
Cancer Cell. 2017 Sep 11;32(3):377-391.e9
pubmed: 28898698
Cell Metab. 2016 Nov 8;24(5):685-700
pubmed: 27829138
Pharmacol Ther. 1994;64(3):445-75
pubmed: 7724657